RVMD Q1 2025 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$20B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$241M

Net Income

-$213M

EPS (Diluted)

$-1.13

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$194M

Free Cash Flow

-$198M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$2.4B

Total Liabilities

$287M

Stockholders' Equity

$2.1B

Cash & Equivalents

$334M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$241M	-$141M	-70.9%
Net Income	-$213M	-$116M	-84.0%